STOCK TITAN

Capricor Therapeutics (CAPR): Millennium stake slips under 5%

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Capricor Therapeutics, Inc. (CAPR) is the subject of a Schedule 13G reporting the equity position of Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander in Capricor’s common stock. The reporting persons disclose beneficial ownership of 2,857,387 Capricor shares, representing 4.9% of the outstanding common stock, with no sole voting or dispositive power and full holdings under shared voting and shared dispositive power.

The group states that it acquired more than 5% of Capricor’s outstanding common stock on August 17, 2026, but by the date of this report its beneficial ownership had fallen to 5% or less. The filing explains that the securities are held by entities over which Millennium-related managers have voting control and investment discretion, and it disclaims that this structure alone constitutes an admission of beneficial ownership.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 2,857,387 shares Capricor common stock reported as beneficially owned by the group
Percent of class 4.9% Percentage of Capricor common stock class beneficially owned
Sole voting power 0 shares Capricor shares over which the group has sole voting power
Shared voting power 2,857,387 shares Capricor shares over which the group has shared voting power
Sole dispositive power 0 shares Capricor shares over which the group has sole dispositive power
Shared dispositive power 2,857,387 shares Capricor shares over which the group has shared dispositive power
Date exceeded 5% ownership August 17, 2026 Date on which beneficial ownership first rose above 5% of the class
beneficial ownership financial
"After acquiring beneficial ownership of more than 5% of the outstanding Common Stock"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power financial
"Shared Voting Power 2,857,387.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
dispositive power financial
"Shared Dispositive Power 2,857,387.00"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
Schedule 13G regulatory
"Capricor Therapeutics, Inc. is the subject of a Schedule 13G reporting"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

What percentage of Capricor Therapeutics (CAPR) does Millennium currently report owning?

Millennium and related reporting persons disclose beneficial ownership of 4.9% of Capricor Therapeutics’ common stock. This equals 2,857,387 shares, all reported under shared voting and shared dispositive power, with no sole voting or sole dispositive authority indicated in the Schedule 13G.

How many Capricor (CAPR) shares are reported as beneficially owned by Millennium?

The reporting group lists beneficial ownership of 2,857,387 shares of Capricor common stock. These shares are attributed to entities over which Millennium-related managers have voting control and investment discretion, and are reported entirely as shared voting and shared dispositive power positions.

Did Millennium’s beneficial ownership in Capricor (CAPR) exceed 5% at any point?

The filing states the reporting persons acquired more than 5% of Capricor’s outstanding common stock on August 17, 2026. By the date of the Schedule 13G, their beneficial ownership had decreased, so they reported holding 5% or less of the class.

What voting power does Millennium report over its Capricor (CAPR) shares?

The Schedule 13G shows 0 shares with sole voting power and 2,857,387 shares with shared voting power. Sole dispositive power is also 0 shares, while all 2,857,387 shares are reported with shared dispositive power across the reporting entities.

Who are the reporting persons in this Capricor (CAPR) Schedule 13G filing?

The reporting persons are Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. The filing explains that securities are held by entities under their voting control or investment discretion, while expressly stating this does not itself admit beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





14070B309

(CUSIP Number)
08/17/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:08/18/2026
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:08/18/2026
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:08/18/2026
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of August 18, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.